Galapagos (GLPG) Expected to Announce Quarterly Earnings on Wednesday

Key Points

• Galapagos will report Q1 2026 results after the market close on Wednesday, May 6, with analysts forecasting ($0.13) EPS and $39.579 million in revenue; the earnings call is set for May 7 at 8:00 AM ET.
• Although the company reported $13.92 EPS and $1.06 billion revenue in the last quarter, analysts now expect steep losses of about -$7 EPS for the current fiscal year and -$2 for the next, and the consensus street rating is "Hold" with an average target of $36.50.
• Shares trade around $28.42 (52‑week range $24.74–$37.78) with a $1.87 billion market cap and a negative P/E; institutional ownership is ~32%, with several funds (notably Millennium Management) increasing their positions recently.

Galapagos (NASDAQ:GLPG - Get Free Report) is projected to issue its Q1 2026 results after the market closes on Wednesday, May 6th. Analysts expect the company to announce earnings of ($0.13) per share and revenue of $39.5790 million for the quarter. Parties can check the company's upcoming Q1 2026 earning summary page for the latest details on the call scheduled for Thursday, May 7, 2026 at 8:00 AM ET.

Galapagos (NASDAQ:GLPG - Get Free Report) last released its quarterly earnings results on Sunday, February 15th. The biotechnology company reported $13.92 earnings per share for the quarter. The firm had revenue of $1.06 billion during the quarter. On average, analysts expect Galapagos to post $-7 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Galapagos Stock Performance

NASDAQ:GLPG opened at $28.42 on Wednesday. Galapagos has a fifty-two week low of $24.74 and a fifty-two week high of $37.78. The stock has a market capitalization of $1.87 billion, a P/E ratio of -18.10 and a beta of 0.32. The company's 50-day simple moving average is $31.07 and its 200-day simple moving average is $32.03.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on GLPG shares. Wall Street Zen upgraded shares of Galapagos from a "hold" rating to a "buy" rating in a research note on Saturday, March 28th. Royal Bank Of Canada lifted their target price on shares of Galapagos from $32.00 to $33.00 and gave the stock a "sector perform" rating in a research note on Tuesday, February 24th. UBS Group reiterated a "market perform" rating on shares of Galapagos in a research note on Tuesday, February 24th. Raymond James Financial reiterated a "market perform" rating on shares of Galapagos in a research note on Tuesday, February 24th. Finally, Weiss Ratings upgraded shares of Galapagos from a "sell (d)" rating to a "hold (c)" rating in a research note on Thursday, February 26th. One investment analyst has rated the stock with a Strong Buy rating, five have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of "Hold" and an average target price of $36.50.

Institutional Trading of Galapagos

A number of institutional investors have recently bought and sold shares of GLPG. XTX Topco Ltd increased its holdings in shares of Galapagos by 92.6% during the 4th quarter. XTX Topco Ltd now owns 23,219 shares of the biotechnology company's stock valued at $759,000 after purchasing an additional 11,162 shares in the last quarter. Millennium Management LLC increased its holdings in shares of Galapagos by 121.9% during the 4th quarter. Millennium Management LLC now owns 339,354 shares of the biotechnology company's stock valued at $11,097,000 after purchasing an additional 186,452 shares in the last quarter. Man Group plc increased its holdings in shares of Galapagos by 31.5% during the 4th quarter. Man Group plc now owns 47,581 shares of the biotechnology company's stock valued at $1,556,000 after purchasing an additional 11,384 shares in the last quarter. Kotler Kevin purchased a new position in shares of Galapagos during the 4th quarter valued at approximately $2,943,000. Finally, Arax Advisory Partners increased its holdings in shares of Galapagos by 319.2% during the 4th quarter. Arax Advisory Partners now owns 2,335 shares of the biotechnology company's stock valued at $76,000 after purchasing an additional 1,778 shares in the last quarter. 32.46% of the stock is currently owned by institutional investors and hedge funds.

Galapagos Company Profile

Galapagos NV NASDAQ: GLPG is a clinical-stage biotechnology company headquartered in Mechelen, Belgium, focused on the discovery and development of novel small-molecule therapies. Established in 1999 through the merger of Tibotec and Progenix, Galapagos has built a research platform targeting chronic inflammatory diseases, fibrosis and oncology. The company's discovery engine integrates human genetics, translational biology and medicinal chemistry to identify and optimize drug candidates with unique modes of action.

The company's pipeline encompasses multiple programs across various stages of development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.